Kymera Therapeutics is preparing to report data from a mid-stage eczema trial for its lead asset KT-621, a high-scrutiny inflection point for the Massachusetts biotech as it seeks to compete in the immunology market dominated by Sanofi and Regeneron’s Dupixent. The company plans to announce results before year-end, with investment bank analysts calling the upcoming readout among the most impactful immunology-and-inflammation catalyst events of the year. A successful outcome could strengthen Kymera’s broader development ambitions beyond eczema, including chronic spontaneous urticaria and asthma—areas where payers and clinicians are weighing new IL-4/IL-13 and broader pathway strategies. Street forecasts cited in the report project potential KT-621 sales approaching $4 billion by 2035, with more than $3 billion tied to eczema, making the readout consequential for both valuation and competitive positioning.